Daniel Joseph Apel

CFO

Chief Financial Officer

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 1 saleMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (1 ops.)

€192k

Latest filing published 24 Apr 2026 for Arrowhead Pharmaceuticals, INC., €192k. Read the official filing

Filing timeline

BuySale

Daniel Joseph Apel

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

No signal scores available.

Daniel Joseph Apel: trading record in brief

Daniel Joseph Apel (finance chief) discloses dealings in Arrowhead Pharmaceuticals, Inc. to SEC (Form 4). Over a trading history stretching from 6 January 2026 to 22 April 2026, the count stands at 2 filings.

Every open-market trade on record is a sale: 1 sale worth €192k. The rest of the record consists of 1 share grant.

The record was last updated on 24 April 2026 with an open-market sale (€192k) in Arrowhead Pharmaceuticals, Inc. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.